Hikma is introducing droxidopa capsules in dosage strengths of 100 mg, 200 mg and 300 mg.
The medication is the generic of Lundbeck's Northera.
Droxidopa is indicated for the treatment of orthostatic dizziness and light-headedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Droxidopa capsules had a market value of approximately $353 million in the 12 months ended November 2020, according to IQVIA.
“We are pleased to launch droxidopa capsules and to be among the first wave of generics, making this important drug available to customers and patients in the United States," said Brian Hoffmann, Hikma president of generics. "We are committed to diversifying our portfolio through delivering on our pipeline and bringing new products to market, helping us to improve patients’ access to high-quality and affordable generic medicines around the world.”